Nabota is Daewoong Pharmaceutical's botulinum toxin type A from South Korea — the same product marketed in the United States under the brand Jeuveau, where it was FDA-approved for cosmetic indication in 2019. Nabota positions as the premium Korean tier: more rigorous Western regulatory clearance than entry-level Korean brands like Hutox or BO LIFT, but still substantially below Allergan/Xeomin pricing. The HI-PURE protein purification process targets fewer non-toxin proteins than older Korean brands. At VERZO CLINIC Bangkok, Nabota starts at ฿7,000 per treated area.
Pricing is per area. Nabota uses the same unit convention as Allergan/Xeomin (1:1) so unit calculations follow the standard botulinum toxin dosing.
Nabota has the same set of facial indications as Allergan Botox. Clinical effect is equivalent; the main differences from Allergan are price (lower) and length of global track record (shorter, but FDA-approved since 2019).
Nabota at VERZO is roughly 40-60% below the equivalent Allergan Botox per-area cost, sitting between Allergan (premium global) and Hutox (Korean entry value). For patients who want the regulatory comfort of US FDA approval (Jeuveau is FDA-approved) but at Korean pricing, Nabota is the natural choice. International medical-tourism patients sometimes prefer Nabota over Allergan when they want the FDA approval marker without paying the AbbVie price.
Every Nabota injection at VERZO is performed by a Thai Medical Council-licensed aesthetic doctor. Nabota is supplied via the authorised Daewoong distributor with full Thai FDA registration; the patient may inspect lot, expiry, and registration on every vial. Reconstitution is performed in front of the patient. Nabota requires refrigerated cold-chain — VERZO follows the manufacturer protocol throughout.
At VERZO CLINIC Bangkok, Nabota starts at ฿7,000 per area — roughly 40-60% below Allergan Botox (฿9,000-16,000 per area) and 40-50% above Hutox (฿2,500-5,000 per area) at the same clinic. Final cost depends on the unit count needed.
Yes — Nabota and Jeuveau are the same product. Daewoong manufactures the botulinum toxin under the name Nabota in Korea and Asia; Evolus licenses and markets it in the United States under the Jeuveau brand, where it received FDA approval for glabella cosmetic indication in 2019. Same molecule, same HI-PURE purification process, different branding by region.
Same mechanism (botulinum toxin type A), same 1:1 unit ratio. Allergan Botox (฿17,999/100U at VERZO) has the longer global track record (FDA 2002) and broader research base. Nabota (฿7,000/area at VERZO) is FDA-approved as Jeuveau since 2019, with a shorter track record but full US regulatory clearance. Allergan is the safer first choice for patients wanting brand recognition; Nabota is the choice when you want FDA approval at Korean pricing.
Both are Korean. Nabota (Daewoong, ฿7,000/area) is the premium Korean tier — same product as US FDA-approved Jeuveau, more rigorous protein purification. Hutox (Huons, ฿4,999/50U or ฿8,000/100U) is the value Korean tier — KFDA + Thai FDA approved but no US FDA clearance, shorter global track record. Nabota costs about 40-50% more than Hutox per equivalent treatment.
Duration is 3-4 months for facial wrinkles and 4-6 months for masseter (jaw slimming) — clinically equivalent to Allergan Botox in most published studies. VERZO schedules a free day-14 follow-up.
Yes. Nabota is registered with the Thai FDA (อย.) and supplied via the authorised Daewoong distributor in Thailand. Each vial arrives in unbroken Daewoong packaging; the patient may inspect lot, expiry, and Thai FDA registration before reconstitution.
Free consultation and booking via LINE @verzo. VERZO CLINIC is located beside BTS Ekkamai station Exit 1, Bangkok.
Location: VERZO CLINIC, 988-990-992 Sukhumvit Road, near BTS Ekkamai, Bangkok. Open daily 10:00-19:00.
Contact: LINE @verzo | WhatsApp +66-95-326-6644